Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

2.

Alizadeh

AA

,

Eisen

MB

,

Davis

RE

, et al.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

.

Nature

.

2000

;

403

(

6769

):

503

-

511

.

3.

Wilson

WH

,

Wright

GW

,

Huang

DW

, et al.

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

.

Cancer Cell

.

2021

;

39

(

12

):

1643

-

1653.e3

.

4.

Palmer

AC

,

Kurtz

DM

,

Alizadeh

AA

.

Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin

.

N Engl J Med

.

2023

;

389

(

8

):

764

-

766

.

5.

Wallach

JD

,

Sullivan

PG

,

Trepanowski

JF

,

Sainani

KL

,

Steyerberg

EW

,

Ioannidis

JPA

.

Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials

.

JAMA Intern Med

.

2017

;

177

(

4

):

554

-

560

.

6.

Amatya

AK

,

Fiero

MH

,

Bloomquist

EW

, et al.

Subgroup analyses in oncology trials: regulatory considerations and case examples

.

Clin Cancer Res

.

2021

;

27

(

21

):

5753

-

5756

.

7.

Li

G

,

Taljaard

M

,

Van den Heuvel

ER

, et al.

An introduction to multiplicity issues in clinical trials: the what, why, when and how

.

Int J Epidemiol

.

2017

;

46

(

2

):

746

-

755

.

8.

Davis

RE

,

Ngo

VN

,

Lenz

G

, et al.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

.

Nature

.

2010

;

463

(

7277

):

88

-

92

.

9.

Pfeifer

M

,

Zheng

B

,

Erdmann

T

, et al.

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

.

Leukemia

.

2015

;

29

(

7

):

1578

-

1586

.

10.

Morschhauser

F

,

Flinn

IW

,

Advani

R

, et al.

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

.

Lancet Haematol

.

2019

;

6

(

5

):

e254

-

e265

.

11.

Sehn

LH

,

Herrera

AF

,

Flowers

CR

, et al.

Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma

.

J Clin Oncol

.

2020

;

38

(

2

):

155

-

165

.

12.

Sehn

LH

,

Hertzberg

M

,

Opat

S

, et al.

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

.

Blood Adv

.

2022

;

6

(

2

):

533

-

543

.

13.

Terui

Y

,

Rai

S

,

Izutsu

K

, et al.

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma

.

Cancer Sci

.

2021

;

112

(

7

):

2845

-

2854

.

14.

Liu

Y

,

Wuxiao

Z

,

Kong

F

, et al.

A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma

.

Ann Transl Med

.

2022

;

10

(

19

):

1070

.

15.

Segman

Y

,

Ribakovsky

E

,

Avigdor

A

, et al.

Outcome of relapsed DLBCL patients, treated with polatuzumab-BR or polatuzumab-R: real life data

.

Blood

.

2019

;

134

(

suppl_1

):

5321

.

16.

Segman

Y

,

Ribakovsky

E

,

Avigdor

A

, et al.

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

.

Leuk Lymphoma

.

2021

;

62

(

1

):

118

-

124

.

17.

Tsai

C-H

,

Tien

FM

,

Hou

H-A

, et al.

Polatuzumab vedotin-based salvage chemotherapy in the third-line or above treatment for diffuse large B-cell lymphoma

.

Blood

.

2020

;

136

(

suppl 1

):

12

.

18.

Wang

Y-W

,

Tsai

XC-H

,

Hou

H-A

, et al.

Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience

.

Ann Hematol

.

2022

;

101

(

2

):

349

-

358

.

19.

Major

A

,

Cliff

ERS

,

Ermann

DA

,

Durani

U

,

Russler-Germain

DA

.

Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: a survey of clinician impressions

.

EJHaem

.

2022

;

3

(

3

):

930

-

935

.

20.

Lapidari

P

,

Vaz-Luis

I

,

Di Meglio

A

.

Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: a systematic review

.

Crit Rev Oncol Hematol

.

2021

;

157

:

103193

.

21.

Kambhampati

S

,

Saumoy

M

,

Schneider

Y

, et al.

Cost effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

.

Blood

.

2022

;

140

(

25

):

2697

-

2708

.

22.

Vijenthira

A

,

Kuruvilla

J

,

Crump

M

,

Jain

M

,

Prica

A

.

Cost-effectiveness analysis of frontline polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone and/or second-line chimeric antigen receptor T-cell therapy versus standard of care for treatment of patients with intermediate- to high-risk diffuse large B-cell lymphoma

.

J Clin Oncol

.

2023

;

41

(

8

):

1577

-

1589

.

23.

Kambhampati

S

,

Shumilov

E

,

Saumoy

M

, et al.

Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany

.

Br J Haematol

.

2023

;

202

(

4

):

771

-

775

.

24.

Liebers

N

,

Duell

J

,

Fitzgerald

D

, et al.

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

.

Blood Adv

.

2021

;

5

(

13

):

2707

-

2716

.

25.

Vercellino

L

,

Di Blasi

R

,

Kanoun

S

, et al.

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

.

Blood Adv

.

2020

;

4

(

22

):

5607

-

5615

.